Adoptive T cell therapy of solid cancers |
| |
| Authors: | Keith L Knutson Wolfgang Wagner Mary L Disis |
| |
| Institution: | (1) Mayo Clinic College of Medicine, 342D Guggenheim, 200 First St SW, Mayo Clinic, Rochester, MN 55905, USA;(2) Department of Immunology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA;(3) Department of Oncology, University of Washington, Tumor Vaccine Group, 1959 NE Pacific Street, 356527, Seattle, WA 98195, USA |
| |
| Abstract: | The development of immune-based approaches for the treatment of cancer has been actively investigated for many years. One
strategy that has emerged as a potentially effective strategy for the treatment of aggressive established malignancies is
adoptive T cell therapy. The power of this approach has been repeatedly observed in preclinical animal models. However, moving
from homogeneous animal models to the heterogeneous human clinical setting has been very difficult. It is only in recent times
that we have been able to pinpoint the problems of the clinical translation of adoptive T cell therapy. Some of the major
problems are sources of tumor-specific T cells, ex vivo expansion, persistence, and anti-tumor activity. This review overviews
the nature of these problems and some of the emerging solutions.
This article is a symposium paper from the conference “Progress in Vaccination against Cancer 2004 (PIVAC 4)”, held in Freudenstadt-Lauterbad,
Black Forest, Germany, on 22–25 September 2004
Grant support: This grant was supported by K01-CA100764 (KLK) and R01-CA85374 (MLD) |
| |
| Keywords: | Adoptive T cell therapy Cytokine therapy Antibody therapy Vaccines Tumor immunology |
| 本文献已被 PubMed SpringerLink 等数据库收录！ |
|
